Comparing TAK-928 with Docetaxel for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer Resistant to Prior Chemotherapy and Immunotherapy

What this Trial Is About

Lung cancer, specifically non-small cell lung cancer NSCLC, is a common cancer type where abnormal lung cells grow rapidly, disrupting normal lung function. This study focuses on adults with advanced NSCLC that cannot be removed by surgery or has spread to other body parts. Researchers are investigating TAK-928, a new immunotherapy designed to activate immune cells called T cells to better attack tumor cells, comparing it to the standard treatment, docetaxel, in adults whose cancer has resisted prior chemotherapy and immunotherapy. Participants receive either TAK-928, an antibody treatment given by intravenous infusion that targets specific immune pathways to activate T cells and natural killer cells, or docetaxel, a chemotherapy drug also given by intravenous infusion. Treatment may last up to two years depending on response and side effects. This is a randomized study with parallel groups where TAK-928s ability to improve immune response and tumor control is being compared directly to docetaxel. During the study, participants will visit the clinic multiple times for treatment and monitoring. Researchers will assess tumor response using imaging scans, monitor survival, and evaluate safety including side effects. Additional tests will measure immune response, drug levels in the body, and quality of life through questionnaires. Participants will be followed until treatment ends, with assessments continuing to track outcomes for up to 26 months.

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer